Sean Duffy is the co-founder and CEO of Omada Health, a digital behavioral medicine company dedicated to inspiring and empowering people everywhere to live free of chronic conditions like heart disease and type 2 diabetes. In 2016, Omada was named a Technology Pioneer by the World Economic Forum, and in 2015 and 2017, the company was recognized as one of Fast Company’s Most Innovative Companies. Prior to Omada, Sean worked at both Google and IDEO. A former MD/MBA candidate at Harvard, he holds a BS in neuroscience from Columbia University.

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University

Stephanie Tilenius is the Founder and CEO of Vida Health, a digital therapeutics platform that helps individuals overcome chronic mental and physical health conditions once and for all. Vida is deployed at Fortune 500 companies, large national payers, and providers.

Prior to starting Vida, Tilenius was with Kleiner Perkins Canfield & Byers, where she worked primarily with late-stage KPCB portfolio companies, with an emphasis on companies in the Digital Growth Fund.

Prior to Kleiner, Stephanie was at Google, where she was Vice President of Global Commerce and Payments, helping build and launch new products and platforms including Google Wallet, Google Shopping and Google Express.

Before Google, she was at eBay and PayPal for nine years. In her last role, she was SVP of eBay.com and Global Product, where she helped lead the eBay Marketplace turnaround from negative to positive double-digit growth.

Prior to eBay, Stephanie was VP of Merchant Services at PayPal where she built the off-eBay PayPal business from the ground up into a multi-billion business.

Today, she is using her experience in building engaging consumer products to transform healthcare. Vida combines digital therapies with one-on-one health coaching and evidence-based programs to help individuals overcome costly chronic conditions like obesity, diabetes, COPD, and depression.

I am a chemical engineer by education. After my PhD on chemical processes at the Max Planck Institute, I dedicated the first 7 years of my professional life to the chemical industry at companies such as BASF, and Covestro. After several positions in R&D with focus on disruptive innovation and high risk initiatives, I joined the marketing team to develop new businesses for high performance materials in the electronic segment. As part of this role, I elaborated a proposal to transform the existing wound care materials into a new application field, wearables. This brought me closer to the field of Health and awoke my passion for health and wellness as an industry. It was then, in 2015, when I decided to join Bayer HealthCare to drive the digitalization efforts, leading Bayer’s Digital Health Incubator. In 2017 and under the umbrella brand of #G4A we brought many talented individuals with one ambition, “change the experience of health”. Since then, my role heading the Ventures team has been focusing on creating businesses that unlock new revenue streams and boost existing ones, improving people’s life in a connected world.

Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

André is an experienced startup executive, business and sales manager, leader, and strategist. He is an expert in inside and field sales management, pharmaceutical and medical products marketing and sales, commercial strategy planning, and healthcare topics. He has extensive knowledge in B2B and B2C business, software and hardware product portfolios and offerings in the US and Germany. His passion for the impact technology can have on a large scale has been the red thread throughout his career. André holds doctorates from the University of Würzburg in medicine and the University of Freiburg in dental medicine.

André joined Sandoz in June 2018 from his role as CSO at Thermondo GmbH, an integrated energy company offering state-of-the-art energy efficiency services and applying digital process excellence and quality management. This year, The Financial Times named Thermondo #2 fastest growing company in Europe as well as one of the 100 most influential clean-tech companies in the world.
Before that, André was Vice President of Local Sales at Zocdoc, Inc. Zocdoc is an online service that identifies in-network neighborhood physicians, books appointments, shares patient reviews, provides appointment and check-up reminders, and automatically fills in paperwork. Zocdoc is free for patients and available across the United States.

Dr. Megan Jones Bell is Chief Science Officer at Headspace, a leader in the field of digital health and a visionary in making mental health care more effective, affordable, and accessible to all populations. Megan leads the company’s seven-person Health and Science team, which focuses on clinically validating the benefits of meditation with Headspace and commercializing the product within healthcare. Megan also oversees the 65+ clinical research studies conducted by Headspace’s academic partners.

Joel serves as Chief Commercial Officer for Click Therapeutics. Click develops software as prescription medical treatments to improve the lives of patients throughout the world.

For over 25 years Joel has helped payers, employers, providers and suppliers achieve better patient outcomes at a lower cost of care using new health technology. Helping to lead the charge for healthcare innovation, Joel will share how employers, insurers, and other healthcare payers are adopting Click’s clinically-validated digital therapeutics as key components to population health strategies.

While at Johnson & Johnson as Director of Payer Relations and with Walgreens as Vice President of Market Development Joel initiated pay for performance and shared savings models of value-based purchasing with payers and health systems. Joel also led commercial efforts with Sanofi Aventis to help providers contain the exploding costs associated with chronic conditions such as diabetes and cardiovascular disease.

Joel graduated from DePaul University in Chicago and later completed a Fellowship in healthcare leadership with the Washington DC based Advisory Board Company.

Rosemary Ku, MD/MBA/MPH, is a practicing physician dual-board certified in Internal Medicine and Preventive Medicine and the founder of Cure Chronic Disease, the only digital health nonprofit dedicated to reversing multiple chronic diseases at scale. The patent pending technology creates ``n of one`` experiences by generating personalized treatment plans that iterate based on how an individual's conditions respond.

Rosemary previously served as the Chief Medical and Strategy Officer of Restore Health (acquired by Zillion in 2017). Restore Health was one of the most clinically effective digital solutions for factors of metabolic syndrome with a 77% reversal rate. During that time, Rosemary's role spanned clinical leadership, product development, and commercialization. Rosemary completed residency at Kaiser Permanente San Francisco and medical school at Columbia University College of Physicians and Surgeons. She obtained her MPH in Health Policy and Administration from UC Berkeley and MBA from Columbia Business School. Rosemary majored in Molecular Biology with a certificate in Neuroscience at Princeton University.

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.

David Amor is an FDA/ EU Quality/ regulatory expert focused on combination products and digital health. From NDAs and 505(b)(2)s to mobile app 510(k)s and Pre-INDs/ Q-subs, David has worked with over 45 medical device and pharmaceutical companies – large and small alike- supporting and/ or leading regulatory submissions and implementing quality management systems, including alignment of Agile-based SDLC programs to FDA and EU requirements. He co-founded RemindTrac in 2014 (www.remindtrac.com), a digital health company for chronic patients, that continues to pioneer mobile care management systems today, and sold his consulting firm Medgineering in 2016.

David has recently led QA/RA strategy groups at Teva within the Digital Health Group, particularly in development of Agile-based Quality Management Systems, was a Principal Consultant in the CP/DH (Combination Products, Digital Health) group at Qara Partners, and served as the in-house risk management subject matter expert at Abbott (St. Jude Medical). He has served as the Director or VP of Quality at other medical device start-ups including AdrenaCard, Calcula, Enspero Medical and various others, and led multiple organizations through 483 and Warning Letter remediation projects, namely associated with risk management and design history file deficiencies, including Pfizer (Hospira), MID, Boston Scientific and St. Jude Medical.

Ruchita Sinha is Sr. Director of Investments at Sanofi Ventures where she invests in biopharma and digital health opportunities. She led Sanofi’s investments in Inozyme, Omada Health, Evidation Health, Curisium, and also manages investments in Science 37 and Common Sensing. Prior to Sanofi, Ruchita was at GE Ventures, where she served as a board observer for HeadSense Medical and Caremerge and managed GE’s investments in CheckCap (Nasdaq: CHEKU) and HeartFlow. She also managed GE’s seed-stage portfolio of digital health investments in partnership with StartUp Health.

Ruchita has more than 15 years of healthcare experience in pharma, biotech, medical devices, and digital health. Previously, Ruchita was at Pfizer’s Strategy, BD, & Portfolio Management group, and a management consultant with LEK Consulting. Ruchita started her career with Maxygen, an early stage biotech company. She holds an MBA from the University of Chicago, an MS in Cellular and Molecular Biology from the University of Wisconsin-Madison, and a BS in Biochemistry from Mount Holyoke College.

David is the CEO of DigiTx Partners, bringing both business and clinical expertise to venture capital with an extensive background practicing medicine and building healthcare software companies. Most recently, Dr. Kim served as the COO of Lumiata, a venture-backed predictive analytics company positioned at the intersection of data science and medical science. Prior to Lumiata, he spent over a decade as an investor evaluating and growing healthcare companies at MPM Capital and Pinnacle Ventures. Before entering the business sector, David practiced as a general internist and hospitalist at Kaiser South San Francisco where he also served as the Director of Urgent Care and Assistant Chief of Internal Medicine.

Shahram is the Founder and General Partner of Civilization Ventures, a fund focused on supporting cutting-edge innovations in synthetic biology and health tech, including genomics, diagnostics, AI and regenerative medicine. Founded in 2017, Civilization VC has already been recognized by SVB as one of the most active funds in diagnostics. The fund’s disruptive seed portfolio includes CatalogDNA and Evonetix, as well as gene therapy leader Rocket Pharma (NASDAQ: RCKT). Prior to starting Civilization VC, Shahram was a founding executive in several life sciences companies, including Rgenix, a biotech company with first-in-class cancer drugs now in clinical trials, and NextBio, a big data genomics pioneer which he helped grow to over 50 people with millions in sales before it was acquired by Illumina. As an angel investor earlier in his career, Shahram provided the first check into Omada Health and was a seed investor in Counsyl (acq. by Myriad), Bina (acq. by Roche) and Avantome (acq. by Illumina). Shahram obtained his JD from Harvard Law School, where he was elected Editor-in-Chief of the Harvard International Law Journal, and has a BA in Economics from Pomona College.

Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA 17 years ago and takes the responsibility for the national and international business development and licensing activities with payer and physician organisations as well as industry partners. And when not travelling the world for business, he travels the world for leisure.

Chris is the Founder and CEO of Hello Sunday Morning - an organisation that builds digital therapeutics focused on supporting people to change their relationship with alcohol.

LTP is a $313M growth equity fund investing exclusively in digital health and healthcare services. Sasha K. Said is a founding member of the LTP investment team where she sources and structures deals; provides representation for LTP on the Board of Directors; and provides strategic and tactical support to portfolio companies. She has 10 years of investing experience across asset classes, 4 of which were spent with Waypoint Capital, the multi-billion dollar investment group that represents the Bertarelli family. While there she helped launch a $2B life science fund, Gurnet Point Capital, now managed by Chris Viehbacher (former CEO of Sanofi), as well as built their corporate venture group with a strategy in digital health. Prior to Waypoint, Sasha was a Global Long/Short Public Equity and Private Equity Analyst at Water Asset Management, a global hedge fund in New York City.

Sasha serves as a Board Observer on the Boards of Vera Whole Health and Health Catalyst and is a Board Member of Rimedio, an early stage pharma services company. She is founder of Breaking7% (B7), a group of 122 women (51% senior/ 49% junior) in deal making roles in Boston who meet monthly to exchange deals and contacts. She is also an Advisor to Pulse companies, Massachusetts’ digital health accelerator.

Peter Hames is co-founder and CEO of Big Health, a company creating “digital medicine” - automated, digital, behavior change programs for mental health that are as scalable as drugs yet as effective as in person therapy. Peter is an NHS Innovation Fellow, and holds a Masters in Experimental Psychology from Oxford University. It was his own experience of insomnia, and how he overcame it, that inspired him to found Big Health and create Sleepio, a digital sleep improvement program that is now available to over 1 million employees as part of their benefits package.

Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for panic disorder, panic attacks and PTSD. Debra has broad operational and leadership experience in start- ups, corporate and nonprofit organizations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor). Debra holds a B.A., MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of an HBS case study. Given her deep knowledge of digital therapeutics and medical devices, she is now an Advisor to DTxCC and a Consultant in this growing market.

Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.

Mr. Kellogg has worked in the medical device life-science industry for over 27 years and is currently the SVP in charge of medical devices (including RA, QA, GMP, and Clin Ops) at Akili Interactive Labs, Inc. Prior to joining Akili, Mr. Kellogg was an integral member of the founding teams at Follica Bio, Afferent, Corp., Sontra Medical, Inc., and UltraCision, Inc., where he served as the Vice President of Business Operations, Vice President of Product Development, Vice President of R&D, and Director of Engineering, respectively.

In these leadership roles, Mr. Kellogg was focused on commercializing novel medical technology. The technologies included digital therapy, surgical modalities, transdermal analyte detection, point-of-care diagnostics, transdermal drug delivery, neuro-stimulation, and therapeutic drug/device combinations. Additionally, he served in lead project management roles at Mentor Medical, Inc. and Ethicon Endo-Surgery, Inc (J&J). His broad experience includes product development/engineering, regulatory strategy/oversight, clinical design/operations, GMP & QSR establishment/compliance, intellectual property, and business development/strategic partnerships.

Mr. Kellogg graduated with high honors from the University of Massachusetts at Amherst with a BS in Engineering and received his MS and MBA from Northeastern University. He is an inventor on many domestic and international patents and the lead inventor on key patents for the Harmonic Scalpel ($1B/year product). In 2004 he and his team were awarded Popular Science’s “Best of what’s new in health care.”

Matthew Tucker helps healthcare companies solve complex commercial problems so they can grow bigger and faster. With extensive experience leading commercial planning and execution across functional areas, Mr. Tucker has leveraged his leadership roles at Highmark Health, Baxter, Mylan, and a number of startups. Over the course of his career, he has led significant growth in health plan initiatives and of more than 20 medical device and pharmaceutical brands.

David Lee is a Partner within the Life Sciences division at Simon-Kucher. David’s focus is on helping clients in the transition to a digital business.

Specifically, David helps digital, medical technology, and pharmaceutical clients drive growth through monetization strategy, sales force optimization, key account negotiation, and commercial excellence programs with an eye toward digitalization.

Professor Kim Cornish is the Director for the Monash Institute of Cognitive and Clinical Neurosciences (MICCN). She is a pioneer in the field of cognitive neuroscience, having defined attention pathways and their trajectories across development in children with brain disorders. This work has provided the foundation for TALI Train - the world’s first interactive, game-based attention training program for children with attention deficits.

Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-validated digital therapeutic solutions into mainstream healthcare through education, advocacy, and research.

With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.

A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.

Abhishek is the Co-founder and CEO of Wellthy Therapeutics, a digital therapeutics company which inspires and enables people to prevent and manage their chronic health conditions and is in the process, pioneering an entirely new category of medicine in Asia.

Wellthy’s first therapeutic in Type-II diabetes has been endorsed as a prescription-grade intervention by the RSSDI, Asia’s largest Diabetes research organisation and is currently prescribed by over 300 physicians in India. Since its inception in 2015, Wellthy has conducted over 13 research studies to validate it outcomes, enrolled more than 7000 participants, collected over a million behavioral data points and entered into strategic partnerships with over 7 enterprises across healthcare to transform the preventive care landscape in emerging markets.

Abhishek holds a B.S. in Chemical and Biomolecular Engineering from The Georgia Institute of Technology and an MBA from the Indian School of Business (ISB).

Abhishek has previously spoken about the role of digital therapeutics in addressing the chronic disease burden at several conferences including 78th Scientific Session of the American Diabetes Association in Orlando, The Clinically Validated Digital Therapeutics Summit in Boston, the NASSCOM Healthtech Summit in Bangalore and the Health and Retirement Conference organised by the Singapore Actuarial Society.

Chin-Wei Soo is the Global Regulatory Head, Combination Products and Devices at Roche/Genentech. He is accountable to provide technical regulatory oversight to Roche’s entire device, combination product, and digital health portfolio, covering all large (BLA) and small molecules (NDA) throughout the product lifecycle. Chin has built a global regulatory team and led the team to secure regulatory approvals for combination products globally.

Chin has 18 years of regulatory and quality experience, including strong expertise in combination products and digital health. Prior to joining Genentech, he was with Medtronic and Boston Scientific where he successfully led regulatory submissions and implemented quality management principles that resulted in approvals of IN.PACTTM drug-device coated balloon, TAXUSTM drug-device coated stent, and implantable, programmable drug infusion pumps.

Chin graduated from Iowa State University with a Bachelor degree in Industrial and Manufacturing Systems Engineering, a Master of Science in Bioscience regulatory affairs from the Johns Hopkins University, and a Doctorate in Regulatory Policy from the University of Southern California School of Pharmacy.

As Senior Vice President of client strategy and development, Derek designs and implements strategies for EnvoyHealth clients. His team ensures that clients can access existing and emerging solutions. Derek has more than 15 years of healthcare experience. He has held various roles at Lash Group, an AmerisourceBergen company, including vice president of operations. He also led Lash Group’s strategic account management team, which provided strategic insight and planning to support biotech and pharmaceutical manufacturers.

Derek received a master’s degree in health administration and business and a Bachelor of Science from the University of South Carolina. Since 2014, he has served on the board of directors for a free medical clinic for low-income residents of Charlotte, North Carolina.